CN Patent

CN107936008B — 氘代化合物及其医药用途

Assigned to Jingluweidai Information Consulting Service Beijing Co ltd · Expires 2022-06-14 · 4y expired

What this patent protects

氘代化合物及其医药用途。本发明涉及结构式I所代表的化合物及其非毒性药学上可接受的盐： R1、R2、R3、R4分别为甲基(‑CH 3 )或三氘代甲基(‑CD 3 )，其中至少有一个为‑CD 3 。该类左旋四氢帕马汀的氘代衍生物，不但药理作用显著提高，而且心脏副作用及肝脏毒性显著降低，个体差异显著降低。

USPTO Abstract

氘代化合物及其医药用途。本发明涉及结构式I所代表的化合物及其非毒性药学上可接受的盐： R1、R2、R3、R4分别为甲基(‑CH 3 )或三氘代甲基(‑CD 3 )，其中至少有一个为‑CD 3 。该类左旋四氢帕马汀的氘代衍生物，不但药理作用显著提高，而且心脏副作用及肝脏毒性显著降低，个体差异显著降低。

Drugs covered by this patent

Patent Metadata

Patent number
CN107936008B
Jurisdiction
CN
Classification
—
Expires
2022-06-14
Drug substance claim
No
Drug product claim
No
Assignee
Jingluweidai Information Consulting Service Beijing Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.